This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 1999, p. 2806-2807, Vol. 43, No. 11
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Activities of Gemifloxacin (SB 265805, LB20304) against Recent Clinical Isolates of Chlamydia pneumoniae

Patricia M. Roblin, Tamara Reznik, Andrei Kutlin, and Margaret R. Hammerschlag*

Division of Infectious Diseases, Department of Pediatrics, Health Science Center at Brooklyn, State University of New York, Brooklyn, New York 11203

Received 11 June 1999/Returned for modification 29 July 1999/Accepted 31 August 1999

We compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates of Chlamydia pneumoniae. Gemifloxacin was the most active quinolone tested, with a MIC at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 µg/ml, but this activity was less than those of doxycycline and erythromycin.

* Corresponding author. Mailing address: Department of Pediatrics, Box 49, SUNY Health Science Center at Brooklyn, 450 Clarkson Ave., Brooklyn, NY 11203-2098. Phone: (718) 245-4075. Fax: (718) 245-2118. E-mail: mhammerschlag{at}pol.net.

Antimicrobial Agents and Chemotherapy, November 1999, p. 2806-2807, Vol. 43, No. 11
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Baltch, A. L., Bopp, L. H., Smith, R. P., Michelsen, P. B., Ritz, W. J. (2005). Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother 56: 104-109 [Abstract] [Full Text]  
  • Yoo, B. K, Triller, D. M, Yong, C.-S., Lodise, T. P (2004). Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections. The Annals of Pharmacotherapy 38: 1226-1235 [Abstract] [Full Text]  
  • Morrissey, I., Salman, H., Bakker, S., Farrell, D., Bebear, C. M., Ridgway, G. (2002). Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother 49: 757-761 [Abstract] [Full Text]  
  • Kutlin, A., Roblin, P. M., Hammerschlag, M. R. (2002). Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother 49: 763-767 [Abstract] [Full Text]  
  • García, I., Pascual, A., Ballesta, S., Joyanes, P., Perea, E. J. (2000). Intracellular Penetration and Activity of Gemifloxacin in Human Polymorphonuclear Leukocytes. Antimicrob. Agents Chemother. 44: 3193-3195 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»